**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 6188**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (1): Hepatocellular carcinoma

Transarterial chemoembolization and bland embolization for hepatocellular carcinoma

Tsochatzis EA *et al*. TA(C)E for HCC

Emmanuel A Tsochatzis, Evangelia Fatourou, James O’Beirne, Tim Meyer, Andrew K Burroughs

**Emmanuel A Tsochatzis, Evangelia Fatourou, James O’Beirne, Andrew K Burroughs,** The Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute of Liver and Digestive Health, London NW3 2QG, United Kingdom

**Tim Meyer,** Department of Oncology, Royal Free Hospital and UCL, London NW3 2QG, United Kingdom

**Author contributions:** Tsochatzis EA prepared the first draft of this manuscript; All authors reviewed the manuscript for important intellectual content and approved the final version.

**Correspondence to: Emmanuel A Tsochatzis, MD, MSc, FEBTM, PhD,** Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute of Liver and Digestive Health, Pond Street, London NW3 2QG, United Kingdom. mtsochatzis@hotmail.com

**Telephone:** +44-20-77940500-35228 **Fax:** +44-20-74726226

**Received:** October 7, 2013  **Revised:** December 23, 2013

**Accepted:** January 8, 2014

**Published online:**

**Abstract**

Transarterial chemoembolization (TACE) is the first line treatment for patients with intermediate stage hepatocellular carcinoma (HCC) but is also increasingly being used for patients on the transplant waiting list to prevent further tumor growth. Despite its widespread use, TACE remains an unstandardized procedure, with variation in type and size of embolizing particles, type and dose of chemotherapy and interval between therapies. Existing evidence from randomized controlled trials suggest that bland embolization (TAE) has the same efficacy with TACE. In the current article, we review the use of TACE and TAE for hepatocellular carcinoma and we focus on the evidence for their use.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Cirrhosis; Hepatocellular carcinoma; Mortality; Embolization; Transarterial chemoembolization; Transarterial embolization; Prognosis

**Core tip:** In the current article, we review the use of transarterial chemoembolization (TACE) and transarterial embolization (TAE) for hepatocellular carcinoma and we focus on the evidence for their use. Apart from their use in intermediate stage hepatocellular carcinoma, we also review the evidence for their use as neo-adjuvant treatment in the pre-transplant setting. We also highlight the fact that there is no conclusive evidence for superiority of TACE over TAE.

Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide with over 500000 new cases diagnosed each year and the third most common cause of cancer-related death[[1](#_ENREF_1)]. Its incidence in Europe is 3.6-10.6/100000 persons[[2](#_ENREF_2)] and rises to 16/100000 persons worldwide[[3](#_ENREF_3)].

Mortality rates remain high and only 5% of patients survive at 5 years after diagnosis; this is largely due to the fact that diagnosis is most often delayed, with only 15% of patients eligible for surgical procedures such as resection and liver transplantation, 50% for non-surgical therapies and 35% or more for best supportive care at diagnosis[[3](#_ENREF_3)]. Both the American (AASLD)[[4](#_ENREF_4)] and European (EASL) Associations for the Study of the Liver[[5](#_ENREF_5)] have recently published updated guidelines for the management of HCC. These are based on a stratification of patients according to the Barcelona Clinic Live Cancer (BCLC) classification, which classifies patients according to tumor burden, liver function as assessed by Child-Pugh score, and performance status, into five distinct prognostic categories with different first line treatment recommendations[[6](#_ENREF_6)].

Intermediate stage HCC or stage B according to BCLC, consists of multi-nodular tumors in patients with Child-Pugh A or B cirrhosis and good performance status[[7](#_ENREF_7)]. The recommended first line treatment for these patients is transarterial chemoembolization[[8](#_ENREF_8)]. It should be noted that patients with intermediate stage HCC are considered a heterogeneous group with different prognoses and responses to treatment leading to both European and Asian experts identifying the need for further sub-classification[[9](#_ENREF_9), [10](#_ENREF_10)]. This could be based on tumor size and Child-Pugh score[[10](#_ENREF_10)]. Indeed, in carefully selected patients with preserved liver function intermediate HCCs, hepatic resection could be a more effective therapeutic option than TACE[[11](#_ENREF_11)]. The future use of molecular signatures and markers might further enhance the classification and prognosis[[12](#_ENREF_12)].

In the current article, we review the use of transarterial embolization with (TACE) or without (TAE) the use of chemotherapeutic agents for HCC focusing on the evidence for their use.

**TACE AND TAE**

The normal liver receives a dual blood supply from the hepatic artery (25%) and the portal vein (75%). As HCC grows, it increasingly depends on the hepatic artery for blood supply and once a tumor nodule reaches a diameter of 2 cm or more, most of the blood supply derives from the hepatic artery. This unique property of HCC provides the rationale for the use of transarterial therapies. TACE and TAE consist of the selective angiographic occlusion of the tumor arterial blood supply with a variety of embolizing agents, with or without the precedence of local chemotherapy infusion. The occlusion by embolic particles results in tumour hypoxia and necrosis, while the addition of local chemotherapy could have an additive anti-tumour effect.The efficacy of TA(C)E was established by a meta-analysis published a decade ago that included 6 randomized controlled trials (RCTs), of which only two were positive, and showed improved two-year survival (HR = 0.53; 95%CI: 0.32–0.89: *P =* 0.017)[[13](#_ENREF_13)]. Patients included in those trials were not staged according to BCLC, as this was not available at that time, and selection criteria differed from current recommendations. More recently our updated meta-analysis, which included nine RCTs also demonstrated a survival benefit of TA(C)E compared to best supportive treatment (HR = 0.705; 95%CI: 0.5–0.99)[[14](#_ENREF_14)]. A recent Cochrane meta-analysis, including nine RCTs with 645 participants, failed to demonstrate a survival benefit with TA(C)E *vs* best supportive care (HR = 0.88; 95%CI: 0.71-1.10) and concluded that an additional 383 participants would need randomization for a potential benefit to be demonstrated[[15](#_ENREF_15)]. This meta-analysis was heavily criticized for the exclusion of positive RCTs due to risk of bias and inappropriate inclusion of trials using gelfoam with short follow-up or enrolling patients with early stage HCC[[16](#_ENREF_16)]. The inconsistency in the results of randomized trials reflects the fact the TA(C)E is not a standardized procedure both in terms of patient selection and the procedure itself.

**PATIENT SELECTION AND SURVIVAL**

According to current treatment guidelines, TA(C)E is not a curative treatment and should be considered as first line treatment in patients with intermediate HCC. In clinical practice however TACE is frequently used outside these recommendations in a wide range of patients ranging from early HCC to advanced liver disease with ascites. Therefore, the variation in reported survival is likely to be dependent on patient selection as well as TA(C)E schedule and techniques.

A retrospective Italian study compared the results of TACE before and after the implementation of BCLC criteria in 2002; In the 1999-2002 period, there was no significant difference in survival between TACE-treated and untreated patients, while in the 2003-2006 period, TACE-treated patients survived longer (*P* < 0.0001) following the significant increase in Child Pugh class A patients and advanced HCC[[17](#_ENREF_17)]. Another retrospective Italian study, including 614 elderly and 1104 younger patients with HCC, showed that overall applicability of HCC treatments was unaffected by older age although treatment distribution differed, with elderly individuals being more frequently treated with percutaneous procedures and less frequently with resection or TACE[[18](#_ENREF_18)]. A retrospective Chinese study that included 1,516 patients with HBV-related cirrhosis and BCLC stage B HCC, all of who received TACE as first line treatment, reported 1-, 3- and 5-year overall survival rates of 84%, 29% and 19% respectively[[19](#_ENREF_19)]. Child-Pugh A liver function and smaller tumor were associated with treatment response. Tumor response after initial TACE, an independent prognostic factor of overall survival, was associated with tumor extent and influenced subsequent treatment[[19](#_ENREF_19)].

A Spanish cohort study of a highly selected patients, 40% of whom were staged as BCLC-A, reported a median survival of 48.6 mo following TACE with pre-loaded drug eluting beads (DEB-TACE) after a median follow up of 24.5 mo[[20](#_ENREF_20)]. Unfortunately, this conclusion was based on projected and not actual data, as at the time point of median survival, less than 15 patients were still at risk of death according to the Kaplan-Meier curve and 35 had died, *i.e.*, there was no adequate follow up for at least 50% of the cohort[[21](#_ENREF_21)]. A Japanese retrospective study reported the outcomes of TACE in 4966 patients diagnosed between 2000 and 2005 across all spectrums of Child Pugh classes and tumor size; overall median and 5-year survivals were 3.3 years and 34%, respectively[[22](#_ENREF_22)]. Not surprisingly, the study showed that the survival rate decreased as the tumor number and size increased in all but one subgroup in both Child-Pugh-A and –B[[22](#_ENREF_22)].

**TA(C)E TECHNIQUES**

A systematic review of 175 cohort and randomized trials of transarterial therapies for HCC exposed the huge heterogeneity in the protocols used, with variable use of embolic and chemotherapeutic agents, variable embolization particle sizes, different schedules and indications for repeat sessions and different arterial selectivity for embolization[[23](#_ENREF_23)].

***EMBOLIZING AGENTS***

Over the years, a variety of embolizing agents have been used, from gelfoam to polyvinyl alcohol (PVA) particles and more recently drug eluting beads.

Gelfoam, which consists of gelatin sponge particles, was used in the first trials of TACE and is a suboptimal embolizing agent, due to the large size of the particles (1 mm) and the temporary occlusion of the tumor feeding arteries that only lasts for two weeks[[24](#_ENREF_24), [25](#_ENREF_25)].

PVA particles provide more permanent arterial occlusion and can potentially provide more distal arterial obstruction as their size can be as small as 45-150 microns[[25](#_ENREF_25)]. A recent study with histopathological analysis of embolized tumors confirmed that smaller PVA particles can reach and occlude more distal arteriolar capillaries and result in slightly better tumor necrosis rate after TACE [[26](#_ENREF_26)]. Moreover, a non-randomized trial comparing different embolizing agents, demonstrated that the number of TACE sessions was significantly greater for the gelfoam powder group (mean, 2.2) *vs* the PVA group (mean, 1.6; *P =* 0.01), although survival did not significantly differ [[27](#_ENREF_27)].

Drug-eluting beads (DEBs; Biocompatibles, Surrey, UK) is a novel system consisting of embolic microspheres preloaded with doxorubicin, that ensure the controlled release of chemotherapy and thus provide a combined local ischaemic and cytotoxic effect[[28](#_ENREF_28)]. This results in lower systemic doxorubicin concentrations than conventional TACE and higher intra-tumor retention[[28](#_ENREF_28)]. However, a phase II RCT comparing DEB-TACE with conventional TACE failed to demonstrate a superiority of DEB-TACE in tumor response[[29](#_ENREF_29)]. Drug related adverse events and liver toxicity were lower in the subgroup of patients with Child Pugh B class and bi-lobar tumors, allowing better adherence to treatment protocol and higher objective response rates in this particular subgroup[[29](#_ENREF_29)]. It should be noted that conventional TACE was not standardized and a variety of embolizing particles and treatment schedules were used, according to the preferences of the treating physician. A RCT comparing TACE with DEBs and TAE with the same particles but without chemotherapy, failed to demonstrate any significant differences in survival or tumor response, further questioning the efficacy of the preloaded chemotherapy[[30](#_ENREF_30)]. DEBs are more expensive than conventional TA(C)E with as yet unproven superiority. However they do represent an important step towards the standardization of the technique and might increase tolerability in sicker patients[[7](#_ENREF_7)].

**CHEMOTHERAPEUTIC AGENTS**

Doxorubicin and cisplatin, followed by epirubicin, are the most commonly used chemotherapeutic agents but none has proven superior to date[[23](#_ENREF_23)] and the choice usually relies on local protocols and physicians preferences. The dosing of chemotherapeutic agent also varies among centres. The median dose in published trials per session of doxorubicin, cisplatin and epirubicin was 50 mg, 92 mg and 50 mg respectively[[23](#_ENREF_23)]. There is no consensus if a standard dose for all patients should be used or a dose adjusted to the body surface area or whether the bilirubin level or other measure of liver function is preferrable. As already mentioned, patients with more advanced liver disease might benefit from DEB-TACE due to lower systemic chemotherapy concentrations. Higher chemotherapeutic doses did not significantly enhance the anticancer effects and survival compared that with lower doses in a study published a decade ago[[31](#_ENREF_31)].

**FREQUENCY OF TA(C)E SESSIONS**

The frequency of TA(C)E has not been adequately addressed to date. From an oncological point of view, chemotherapy should be administered at 3-week intervals in order to fit to the cell cycle[[8](#_ENREF_8)]. However, such a strategy would carry the risk of increased side effects and indeed patients with an initial good response would not necessarily benefit. A repeat “on demand” strategy of conventional TACE was recently retrospectively evaluated in 151 consecutive patients. Complete response and recurrence rates after first and second TACE were similar, with 64% of patients being submitted to second TACE and 26% to third TACE using an "on demand" policy[[32](#_ENREF_32)] based on tumor response. We have reported the case of a patient with 10 “on demand” TAE over a 5-year period with repeated radiological response[[33](#_ENREF_33)].

**ADVERSE EFFECTS**

The most common adverse effect of TA(C)E is the post-embolization syndrome, which is manifested by abdominal pain, fever and elevated liver function tests in the first 24-48 h post-treatment and only requires supportive measures[[34](#_ENREF_34)]. Deterioration of liver function with development of ascites and even liver failure occurs in a minority of patients and depends on liver reserve pre-TACE and selectivity of embolisation. Our systematic review reported a median treatment related mortality of 2.4% in 37 trials including 2878 patients[[23](#_ENREF_23)],however this is influenced by patient selection. A recent Japanese cohort study reported treatment related mortality of 0.38% (19/4966 patients)[[22](#_ENREF_22)]. However, in the presence of ascites, 17% of patients with develop liver failure post-TACE and tha vast majority of them will die within a year[[35](#_ENREF_35)]. Other TACE-induced adverse events include the formation of liver abscess in the necrotic tumor, bile duct injury and ischaemic cholecystitis[[7](#_ENREF_7)].

**TAE OR TACE**

TACE is reported as the preferred transarterial therapy of choice in the literature[[1](#_ENREF_1), [3](#_ENREF_3)] and EASL guidelines[[5](#_ENREF_5)], despite the fact that this claim is not supported by existing evidence[[36](#_ENREF_36), [37](#_ENREF_37)]. From a pathophysiological point of view, TACE in most centres consists of the chemotherapy and embolization administered at the same time. As hypoxia is a known cause of chemo-resistance, the rational for administering chemotherapy while rendering the tumour hypoxic is questionable[[38](#_ENREF_38)].

We recently published an updated meta-analysis of five RCTs comparing TACE with TAE, where we found no difference in survival[[39](#_ENREF_39)]. Since then, a sixth RCT was published in abstract form, also with unequivocal results[[40](#_ENREF_40)]. All these published RCTs are summarized in Table 1[[30](#_ENREF_30), [39-43](#_ENREF_39)]. The last three RCTs used permanent occluding embolizing particles[[30](#_ENREF_30), [39](#_ENREF_39), [40](#_ENREF_40)], as opposed to gelfoam used in the rest[[41-43](#_ENREF_41)].

In the study by Malagari *et al*[[30](#_ENREF_30)], 84 patients were randomized to either DEB-TACE or embolization alone using BeadBlocks (100-300 or 300-500 microns diameter). There was no difference in 1-year surviaval, (86% *vs* 85.3% in DEB-TACE and TAE respectively) despite the fact that the DEB-TACE group had a statistically significant longer time to tumour progression. The RCT performed by our group was a phase II/III trial of three weekly cisplatin based TACE *vs* TAE with PVA particles (diameter 40-150 microns) as the embolizing agent[[39](#_ENREF_39)]. The median overall survival and progression-free survival was 17.3 *vs* 16.3 (*P =* 0.74) mo and 7.2 *vs* 7.5 (*P =* 0.59), in the TAE and TACE groups respectively[[39](#_ENREF_39)]. Finally, the RCT by Brown published in abstract form, compared DEB-TACE with TAE with BeadBlocks and reported no significant differences in progression-free survival (7 mo *vs* 9 mo) and overall suvival (16 mo *vs* 14 mo)[[40](#_ENREF_40)].

These data clearly demonstrate that TAE is equally effective as TACE at a lower cost and with potentially fewer side effects due to the lack of chemotherapy[[7](#_ENREF_7)]. This lack of additional effect of chemotherapy could be due to the infrequent intervals of TACE of several mo that do not follow the usual oncological chemotherapy principles that target certain cell cycle phases[[44](#_ENREF_44)]. They could also be attributed to the chemoresistance that results from tumour hypoxia induced by embolization[[38](#_ENREF_38)]. We therefore advocate that the use of permanently occluding embolizing agent is more important than the use of chemotherapy.

**ASSESSMENT OF TREATMENT RESPONSE**

Traditionally, tumor response was assessed with the RECIST criteria, which are based on the sum of unidimensional measurements of tumor lesions and therefore require tumor shrinkage in order to document response. Transarterial therapies for HCC exert their therapeutic effect by tumor devascularization and necrosis, which is not always accompanied with reduction in size. In order to address this, EASL advocated the measurement of change in tumor enhancement on contrast enhanced imaging (EASL criteria), while AASLD proposed the modified RECIST criteria (mRECIST), that also assess changes in tumor arterial enhancement.

It was recently shown in a cohort of 160 consecutive patients with HCC that evaluating the largest two lesions is generally the most useful procedure for measuring TACE responses under both EASL and mRECIST[[45](#_ENREF_45)].

The prognostic implication of treatments response accordnig to mRECIST and EASL compared to RECIST has been assessed in cohort studies. In a cohort of 83 consecutive patients with HCC, we showed that when measured at a single time point after the first transarterial therapy, EASL and mRECIST overall response rates were significantly associated with survival, in contrast with RECIST repsonse rates[[46](#_ENREF_46)]; EASL response was associated with a 44% risk reduction and mRECIST with a 42% reduction. These findings were confirmed in a cohort of 114 Korean patients with HCC, where both EASL response (HR = 0.21, 95%CI: 0.11-0.40, *P <* 0.001) and mRECIST response (HR = 0.31, 95%CI: 0.17-0.59, *P <* 0.001) after 1-2 TACE sessions were independently associated with survival. Similarly, the use of mRECIST and EASL response criteria 1 mo after initial TACE, better predicted the differences in overall survival between responders and non-responders than conventional RECIST criteria[[47](#_ENREF_47)].

**TA(C)E IN PATIENTS WITH PORTAL VEIN THROMBOSIS**

PVT is common in patients with cirrhosis and becomes more prevalent as liver function deteriorates[[48](#_ENREF_48)]. TACE is generally contra-indicated in patients with PVT, due to concerns that a further decrease to the blood supply of the liver can prove deleterious. Nevertheless, this dogma has been challenged and there are uncontrolled trials and cohort studes that suggest a treatment benefit in selected patients wirth preserved liver function[[49](#_ENREF_49), [50](#_ENREF_50)]. A recent meta-analysis including 8 studies with 1601 patients, concluded that TACE in patients with portal vein thrombosis (PVT) improved the 6-month (HR = 0.41; 95%CI: 0.32-0.53) and 1-year (HR = 0.44; 95%CI: 0.34-0.57) survival compared with conservative treatment[[51](#_ENREF_51)]. Nevertheless, studies included in the meta-analysis exhibited significant differences among patient characteristics between the treatment groups, and were ill defined in terms of treatment allocation [[51](#_ENREF_51)]. Until these results are confirmed in RCTs, they need to be interpreted with extreme caution and decisions should be made on an individual patient basis taking into account the radiological expertise of the treating centers. We would only consider TA(C)E in patients with Child A cirrhosis and segmental PVT.

**COMBINATION OF TA(C)E AND PERCUTANEOUS TECHNIQUES**

The effectiveness of percutaneous techniques, mainly represented by radiofrequency ablation (RFA), is reduced as tumour size increases. This is partly due ro the increased blood flow in larger lesions resulting in heat loss and thus less effective ablation[[7](#_ENREF_7)]. Therefore, it seems reasonable to perform RFA after occluding the hepatic arterial flow supplying the tumour with TA(C)E. This would theoretically increase the ablation size of thermal injury as blood flow to and within the tumour is reduced. To date, there have been no large and conclusive RCT assessing dual sequential therapy. In a RCT including 93 patients with tumours less than 3 cm, combination treatment with TACE and RFA did not result in impoved survival compared to RFA alone[[52](#_ENREF_52)], which was a predictable result given the small size of tumours. In another RCT that included 189 patients with tumours < 7 cm, combined RFA and TACE resulted in better overall and tumour free survival than RFA alone[[53](#_ENREF_53)]. There are only cohort studies that compare TACE and RFA *vs* TACE alone and these have shown promising results that warrant adequately powered RCTs[[54](#_ENREF_54), [55](#_ENREF_55)].

**PREDICTION OF TREATMENT RESPONSE AND POST-TREATMENT SURVIVAL**

Survival in patients with HCC depends on both the succesful treatment of the tumor but also on the underlying liver function and reserve[[56](#_ENREF_56)]. Therefore, not surprisingly, survival post transarterial therapies is independently influenced by a combination of tumor and liver function parameters (Table 2).

A simple prognostic score consisting of alpha-fetoprotein ( > 400 U/L), tumor size ( > 50%) and Child-Pugh score was found to predict the survival of patients treated with TACE and could therefore be used to decide which patients with unresectable HCC should receive this therapy; the authors concluded that TACE should not be administered to patients with one or more positive prognostic factors[[57](#_ENREF_57)]. Similarly, it was shown that patients with a persistently increased neutrophil-to-lymphocyte ratio post-TACE have a worse outcome[[58](#_ENREF_58)]. We recently developed and validated a simple prognostic score for post TA(C)E survival, namely Hepatoma arterial-embolisation prognostic (HAP) score, where one point is assigned for each of albumin < 36 g/dL, bilirubin > 17 mumol/L, AFP > 400 ng/mL or size of dominant tumour > 7 cm[[59](#_ENREF_59)]. This is simpler than previously described scores[[57](#_ENREF_57)] and only requires calculation at a single time point rather than serial measurements[[58](#_ENREF_58)].

Similarly, the Assessment for Retreatment with TACE (ART) score was developed and validated in order to guide the decision for retreatment with TACE[[60](#_ENREF_60)]. The increase of AST by > 25%, an increase of Child-Pugh score of 1 (or ≥ 2 points) from baseline, and the absence of radiologic tumor response were used to create the ART score. The ART score differentiated two groups (0-1.5 points; ≥ 2.5 points) with distinct prognosis and a higher ART score was associated with major adverse events after the second TACE[[60](#_ENREF_60)]. The same authors demonstrated that the sequential assessment of the ART-score identifies patients with dismal prognosis prior to each TACE session[[61](#_ENREF_61)].

**TA(C)E PRE-TRANSPLANTATION FOR PATIENTS ON THE WAITING LIST**

Locoregional therapies are increasingly used for patients on the transplant waiting list despite the lack of conclusive data, in order to prevent further growth of the tumor and thus ensure that the patient remains eligible for transplantation until an organ becomes available[[62](#_ENREF_62)]. The recent EASL-EORTC guidelines for HCC recommend neo-adjuvant treatment pre-transplant if the waiting list time is more than 6 mo to prevent dropouts due to tumour progression[[5](#_ENREF_5)]. This was partly based on a Markov model analysis that did not evaluate waiting list times of less than six month[[63](#_ENREF_63)]. Percutaneous techniques, although effective, are not routinely used in the pre-transplant setting in our center because of the small, but not negligible risk, of tumour seeding[[64](#_ENREF_64)].

We recently published our prospectively collected data of patients with HCC treated with TAE on the liver transplant waiting list and we found that pre-transplant TAE significantly reduced post-transplant HCC recurrence in patients within the Milan criteria[[65](#_ENREF_65)]. We have furthter demonstrated that the reduced calcineurin-inhibitor exposure in the first month post-transplant is associated with reduced HCC recurrence[[66](#_ENREF_66)]. Characteristics of tumor response to TACE on the transplant waiting list add a dynamic assessement of tumor biology and were recently suggested as potentially useful in identifying suitable patients for transplantation based on preliminary data from 136 patients[[67](#_ENREF_67)]. Nevertheless, conclusive data on the effects of TA(C)E on dropout rates are lacking.

**TACE COMBINED WITH ANTI-ANGIOGENIC THERAPY**

Sorafenib, a multikinase inhibitor with anti-angiogenic activity, became in 2008 the first systemic therapy that showed a survival benefit in patients with HCC[[68](#_ENREF_68)]. Theoretically, sorafenib could inhibit the growth factors such as VEGF that are synthesized in the tumor tissue in response to the TACE-induced hypoxia and therefore sorafenib may be beneficial as an adjuvant treatment with TA(c)E[[69](#_ENREF_69)]. Conclusive data from phase III trials to support this hypothesis are currently lacking. In a single arm, phase II study, sorafenib was administerd 3 d after TACE for a total period of up to 24 wk, and resulted in a 6-month progression free survival of 52% with an acceptable safety profile[[70](#_ENREF_70)]. Similarly, an interim analysis of the START trial, which is a phase II single arm trial, reported an overall response rate of 52% and no unexpected side-effects[[71](#_ENREF_71)]. Several trials on combinations of TACE with sorafenib but also other agents such as brivanib, sumatinib and thalidomide are registered and currently recruiting[[9](#_ENREF_9), [70](#_ENREF_70)]; a full listing is beyond the scope of these article. Until the results of such RCTs become available, combinations of TACE with targeted therapies should be performed in the context of clinical trials.

**CONCLUSIONS-FUTURE DIRECTIONS**

TAE and TACE should be regarded as equally effective in the management of patients with HCC; their main indication is in patients with intermediate HCC. However they are increasingly used for patients on the liver transplant waiting list in order to prevent further tumor progression. The absence of chemotherapy may make TAE better tolerated particularly in patients with borderline liver function. Despite its use for over two decades, TA(C)E remains an unstandardized procedure, with variations in the size and type of embolizing particles, choice and dose of chemotherapeutic agent, and interval between procedures. Smaller embolising particles may result in more selective embolisation with less damage to surrounding non tumorous tissue. DEB-TACE, is not more effective than conventional TACE, but might contribute towards the standardization of the technique. The results of various combination trials of TA(C)E with sorafenib and other targeted therapies are eagerly awaited and might further improve survival in this patient group.

**REFERENCES**

1 **Forner A**, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0]

2 **Blachier M**, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol* 2013; **58**: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]

3 **El-Serag HB**. Hepatocellular carcinoma. *N Engl J Med* 2011; **365**: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]

4 **Bruix J**, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

5 EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *Eur J Cancer* 2012; **48**: 599-641 [PMID: 22424278]

6 **Llovet JM**, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. *Liver Transpl* 2004; **10**: S115-S120 [PMID: 14762851]

7 **Tsochatzis EA**, Fatourou EM, Triantos CK, Burroughs AK. Transarterial therapies for hepatocellular carcinoma. *Recent Results Cancer Res* 2013; **190**: 195-206 [PMID: 22941022 DOI: 10.1007/978-3-642-16037-0\_13]

8 **Tsochatzis EA**, Germani G, Burroughs AK. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. *Semin Oncol* 2010; **37**: 89-93 [PMID: 20494700 DOI: 10.1053/j.seminoncol.2010.03.007]

9 **Park JW**, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). *Liver Int* 2013; **33**: 327-337 [PMID: 23331661 DOI: 10.1111/liv.12083]

10 **Bolondi L**, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. *Semin Liver Dis* 2012; **32**: 348-359 [PMID: 23397536 DOI: 10.1055/s-0032-1329906]

11 **Zhong JH**, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ. Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma. *Ann Surg* 2013; : [PMID: 24096763 DOI: 10.1097/sla.0000000000000236]

12 **Fatourou EM**, Koskinas JS. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. *Expert Rev Anticancer Ther* 2009; **9**: 1499-1510 [PMID: 19828011 DOI: 10.1586/era.09.103]

13 **Llovet JM**, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 2003; **37**: 429-442 [PMID: 12540794 DOI: 10.1053/jhep.2003.50047]

14 **Maluccio MA**, Covey AM, Porat LB, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, Jarnagin W, Dematteo R, Blumgart LH, Fong Y, Brown KT. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. *J Vasc Interv Radiol* 2008; **19**: 862-869 [PMID: 18503900]

15 **Oliveri RS**, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. *Cochrane Database Syst Rev* 2011; : CD004787 [PMID: 21412886]

16 **Forner A**, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit? *J Hepatol* 2012; **56**: 984-986 [PMID: 22008737 DOI: 10.1016/j.jhep.2011.08.017]

17 **Giannini EG**, Bodini G, Corbo M, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. *Aliment Pharmacol Ther* 2010; **31**: 493-501 [PMID: 19912152 DOI: 10.1111/j.1365-2036.2009.04198.x]

18 **Mirici-Cappa F**, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, Maraldi F, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M, Trevisani F. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. *Gut* 2010; **59**: 387-396 [PMID: 20207642 DOI: 10.1136/gut.2009.194217]

19 **Heng-Jun G**, Yao-Jun Z, Min-Shan C, Mei-Xian C, Jun-Ting H, Li X, Lau WY. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. *Liver Int* 2013; : [PMID: 24028297 DOI: 10.1111/liv.12307]

20 **Burrel M**, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. *J Hepatol* 2012; **56**: 1330-1335 [PMID: 22314428]

21 **Tsochatzis EA**, Meyer T, O'Beirne J, Burroughs AK. Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization. *J Hepatol* 2013; **58**: 194 [PMID: 23046673 DOI: 10.1016/j.jhep.2012.08.028]

22 **Takayasu K**, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. *J Hepatol* 2012; **56**: 886-892 [PMID: 22173160 DOI: 10.1016/j.jhep.2011.10.021]

23 **Marelli L**, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. *Cardiovasc Intervent Radiol* 2007; **30**: 6-25 [PMID: 17103105]

24 **Tsochatzis E**, Meyer T, Marelli L, Burroughs AK. Which transarterial therapy is best for hepatocellular carcinoma?--the evidence to date. *J Hepatol* 2010; **53**: 588 [PMID: 20472319 DOI: 10.1016/j.jhep.2010.01.031]

25 **Coldwell DM**, Stokes KR, Yakes WF. Embolotherapy: agents, clinical applications, and techniques. *Radiographics* 1994; **14**: 623-43; quiz 645-6 [PMID: 8066276 DOI: 10.1148/radiographics.14.3.8066276]

26 **Lee MY**, Chuang VP, Wei CJ, Cheng TY, Cherng MT. Histopathologic correlation of hepatocellular carcinoma after transcatheter arterial chemoembolization with polyvinyl alcohol particle of various sizes. *Eur J Radiol* 2012; **81**: 1976-1979 [PMID: 21628086 DOI: 10.1016/j.ejrad.2011.05.004]

27 **Brown DB**, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC, Crippin JS. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. *J Vasc Interv Radiol* 2005; **16**: 1661-1666 [PMID: 16371533]

28 **Varela M**, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM, Bruix J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. *J Hepatol* 2007; **46**: 474-481 [PMID: 17239480 DOI: 10.1016/j.jhep.2006.10.020]

29 **Lammer J**, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol* 2010; **33**: 41-52 [PMID: 19908093]

30 **Malagari K**, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, Moschouris H, Emmanouil E, Rizos S, Kelekis D. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 2010; **33**: 541-551 [PMID: 19937027]

31 **Lu W**, Li Y, He X, Chen Y. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. *Hepatogastroenterology* 2003; **50**: 2079-2083 [PMID: 14696468]

32 **Terzi E**, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, Giampalma E, Renzulli M, Bolondi L. Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". *J Hepatol* 2012; **57**: 1258-1267 [PMID: 22871502 DOI: 10.1016/j.jhep.2012.07.025]

33 **Marelli L**, Shusang V, Senzolo M, Cholongitas E, Goode A, Yu D, Patch DW, Burroughs AK. Repeated courses of transarterial embolization with polyvinyl alcohol particles: 'long life elixir' in a cirrhotic patient with unresectable hepatocellular carcinoma. *Eur J Gastroenterol Hepatol* 2007; **19**: 329-332 [PMID: 17353698]

34 **Leung DA**, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. *J Vasc Interv Radiol* 2001; **12**: 321-326 [PMID: 11287509]

35 **Hsin IF**, Hsu CY, Huang HC, Huang YH, Lin HC, Lee RC, Chiang JH, Lee FY, Huo TI, Lee SD. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. *J Clin Gastroenterol* 2011; **45**: 556-562 [PMID: 21666547 DOI: 10.1097/MCG.0b013e318210ff17]

36 **Tsochatzis EA**, Meyer T, Burroughs AK. Hepatocellular carcinoma. *N Engl J Med* 2012; **366**: 92; author reply 92-93 [PMID: 22216857 DOI: 10.1056/NEJMc1112501]

37 **Tsochatzis E**, Meyer T, O'Beirne J, Burroughs AK. Transarterial chemoembolisation is not superior to embolisation alone: the recent European Association for the Study of the Liver (EASL) - European Organisation for Research and Treatment of Cancer (EORTC) guidelines. *Eur J Cancer* 2013; **49**: 1509-1510 [PMID: 23231982 DOI: 10.1016/j.ejca.2012.11.012]

38 **Tak E**, Lee S, Lee J, Rashid MA, Kim YW, Park JH, Park WS, Shokat KM, Ha J, Kim SS. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. *J Hepatol* 2011; **54**: 328-339 [PMID: 21056497 DOI: 10.1016/j.jhep.2010.06.045]

39 **Meyer T**, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. *Br J Cancer* 2013; **108**: 1252-1259 [PMID: 23449352 DOI: 10.1038/bjc.2013.85]

40 **Brown KG**, M; Do, KG; Covey, AM; Getrajdam, G; Zhao, B; Sofocleous, CT, Johnson, K; Beattie, C; DeMatteo RP; Solomon, SB; Schwartz, LH; Abou-Alfa, GK. A randomized single blind controlled trial of beads *vs* doxorubicin-eluting beads for arterial embolization of hepatocellular carcinoma (HCC). *J Clin Oncol* 2012; **30** Suppl 34: 134

41 **Kawai S**, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. *Cancer Chemother Pharmacol* 1992; **31** Suppl: S1-S6 [PMID: 1281041 DOI: 10.1007/BF00687096]

42 **Chang JM**, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. *Cancer* 1994; **74**: 2449-2453 [PMID: 7922999]

43 **Llovet JM**, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation *vs* symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002; **359**: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X]

44 **Burroughs A**, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. *Lancet Oncol* 2004; **5**: 409-418 [PMID: 15231247 DOI: 10.1016/S1470-2045(04)01508-6]

45 **Shim JH**, Lee HC, Won HJ, Shin YM, Kim KM, Lim YS, Suh DJ. Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. *J Hepatol* 2012; **56**: 406-411 [PMID: 21782761 DOI: 10.1016/j.jhep.2011.04.028]

46 **Gillmore R**, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. *J Hepatol* 2011; **55**: 1309-1316 [PMID: 21703196 DOI: 10.1016/j.jhep.2011.03.007]

47 **Kim CJ**, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim MJ. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. *Liver Int* 2013; : [PMID: 23890360 DOI: 10.1111/liv.12270]

48 **Tsochatzis EA**, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. *Aliment Pharmacol Ther* 2010; **31**: 366-374 [PMID: 19863496 DOI: 10.1111/j.1365-2036.2009.04182.x]

49 **Chung GE**, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. *Radiology* 2011; **258**: 627-634 [PMID: 21273524 DOI: 10.1148/radiol.10101058]

50 **Luo J**, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. *Ann Surg Oncol* 2011; **18**: 413-420 [PMID: 20839057 DOI: 10.1245/s10434-010-1321-8]

51 **Xue TC**, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. *BMC Gastroenterol* 2013; **13**: 60 [PMID: 23566041 DOI: 10.1186/1471-230x-13-60]

52 **Shibata T**, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? *Radiology* 2009; **252**: 905-913 [PMID: 19567647 DOI: 10.1148/radiol.2523081676]

53 **Peng ZW**, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. *J Clin Oncol* 2013; **31**: 426-432 [PMID: 23269991 DOI: 10.1200/jco.2012.42.9936]

54 **Helmberger T**, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann RT, Löhe F, Graeb C, Rau HG, Schauer R, Jauch KW, Caselmann WH, Göke B, Jüngst D. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. *Digestion* 2007; **75**: 104-112 [PMID: 17598962 DOI: 10.1159/000104730]

55 **Veltri A**, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). *Eur Radiol* 2006; **16**: 661-669 [PMID: 16228211 DOI: 10.1007/s00330-005-0029-9]

56 **Grieco A**, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. *Gut* 2005; **54**: 411-418 [PMID: 15710992 DOI: 10.1136/gut.2004.048124]

57 **Lladó L**, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, Torras J, Fabregat J, Guardiola J, Jaurrieta E. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. *Cancer* 2000; **88**: 50-57 [PMID: 10618605]

58 **Pinato DJ**, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. *Transl Res* 2012; **160**: 146-152 [PMID: 22677364 DOI: 10.1016/j.trsl.2012.01.011]

59 **Kadalayil L**, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. *Ann Oncol* 2013; **24**: 2565-2570 [PMID: 23857958 DOI: 10.1093/annonc/mdt247]

60 **Sieghart W**, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-Radosavljevic M. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. *Hepatology* 2013; **57**: 2261-2273 [PMID: 23316013 DOI: 10.1002/hep.26256]

61 **Hucke F**, Sieghart W, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M. The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. *J Hepatol* 2014; **60**: 118-126 [PMID: 24012941 DOI: 10.1016/j.jhep.2013.08.022]

62 **Cescon M**, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. *J Hepatol* 2013; **58**: 609-618 [PMID: 23041304 DOI: 10.1016/j.jhep.2012.09.021]

63 **Llovet JM**, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, Rodés J, Bruix J. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. *Gut* 2002; **50**: 123-128 [PMID: 11772979]

64 **Stigliano R**, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. *Cancer Treat Rev* 2007; **33**: 437-447 [PMID: 17512669 DOI: 10.1016/j.ctrv.2007.04.001]

65 **Tsochatzis E**, Garcovich M, Marelli L, Papastergiou V, Fatourou E, Rodriguez-Peralvarez ML, Germani G, Davies N, Yu D, Luong TV, Dhillon AP, Thorburn D, Patch D, O'Beirne J, Meyer T, Burroughs AK. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. *Liver Int* 2013; **33**: 944-949 [PMID: 23530918 DOI: 10.1111/liv.12144]

66 **Rodríguez-Perálvarez M**, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-Álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. *J Hepatol* 2013; **59**: 1193-1199 [PMID: 23867318 DOI: 10.1016/j.jhep.2013.07.012]

67 **Otto G**, Schuchmann M, Hoppe-Lotichius M, Heise M, Weinmann A, Hansen T, Pitton MP. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? *J Hepatol* 2013; **59**: 279-284 [PMID: 23587474 DOI: 10.1016/j.jhep.2013.04.006]

68 **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]

69 **von Marschall Z**, Cramer T, Höcker M, Finkenzeller G, Wiedenmann B, Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. *Gut* 2001; **48**: 87-96 [PMID: 11115828 DOI: 10.1136/gut.48.1.87]

70 **Park JW**, Koh YH, Kim HB, Kim HY, An S, Choi JI, Woo SM, Nam BH. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. *J Hepatol* 2012; **56**: 1336-1342 [PMID: 22314421 DOI: 10.1016/j.jhep.2012.01.006]

71 **Chung YH**, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY, Chao Y. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. *Int J Cancer* 2013; **132**: 2448-2458 [PMID: 23129123 DOI: 10.1002/ijc.27925]

**P-Reviewers:** Tomizawa M, Zhong JH  **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**

**Table 1 Randomized controlled trials comparing transarterial embolization with transarterial chemoembolization in patients with hepatocellular carcinoma**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **Patients, *n*** | **Chemotherapy in TACE arm** | **Embolizing agent** | **Outcome in survival** |
| Kawai *et al*[[41](#_ENREF_41)], 1992 | 289 | doxorubicin | Lipiodol+gerlfoam | NS |
| Chang *et al*[[42](#_ENREF_42)], 1994 | 46 | cisplatin | Lipiodol+gerlfoam | NS |
| Llovet *et al*[[43](#_ENREF_43)], 2002 | 77 | doxorubicin | Lipiodol | NS |
| Malagari *et al*[[30](#_ENREF_30)], 2010 | 84 | Doxorubicin-loaded LC beads | BeadBlocks | NS |
| Meyer *et al*[[39](#_ENREF_39)], 2013 | 86 | cisplatin | PVA particles | NS |
| Brown *et al*[[40](#_ENREF_40)], 2012 | 101 | Doxorubicin-loaded LC beads | BeadBlocks | NS |

TACE: Transarterial chemoembolization.

**Table 2 Prognostic scores of survival after transarterial chemoembolization and transarterial embolization**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Parameters** | **Cut-off** | **Comments** |
| Llado *et al*[[57](#_ENREF_57)] | aFP > 400 ng/mLTumor volume > 50%Child-Pugh score | Based on regression co-efficients | Patients classified in 3 categories |
| Pinato *et al*[[58](#_ENREF_58)] | Neutrophil-to-lymphocyte ratio | Significant improvement in survival if NLR stable or normalized post TACE | Radiological response after TACE also associated with survival |
| Kadalayil *et al*[[59](#_ENREF_59)] | albumin<36 g/dLbilirubin > 17 μmol/LAFP > 400 ng/mLDominant tumor > 7 cm | 4 groups based on HAP scores of 0,1,2 and > 2 | Validated in an independent dataset |
| Sieghart *et al*[[60](#_ENREF_60)] | Increase of AST > 25%Increase of Child-Pugh > 1Absence of radiologic tumor response | 0-1.5 points;≥ 2.5 points  | Determines prognosis prior to 2nd TACE; validated in independent cohort |

TACE: Transarterial chemoembolization; HAP: Hepatoma arterial-embolisation prognostic.